https://www.mayo.edu/research/clinical-trials/cls-20592274
Expanded Access Protocol For Nonconforming Afami-cel - Mayo Clinic
Learn more about services at Mayo Clinic.
expanded access protocolafamicelmayoclinic
https://www.newsfilecorp.com/release/185658/Adaptimmune-Reports-Better-Outcomes-for-People-with-Synovial-Sarcoma-who-Received-Afamicel-Compared-to-Historical-Control
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel...
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response...
https://www.biospace.com/adaptimmune-reports-better-outcomes-for-people-with-synovial-sarcoma-who-received-afami-cel-compared-to-historical-control
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel...
Oct 31, 2023 - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, to present outcome data from Cohort 1 of its pivotal SPEARHEAD-1 trial...